912773-24-1

Basic information

• Product Name: 6-Bromoimidazo[1,2-a]pyrazine
• Synonyms: 6-BroMoiMidazo[1,2-a]pyra...;6-BroMoiMidazo[1,2-a;6-BroMoidazo[1,2-a]pyrazine;6-BROMOIMIDAZO[1,2-A]PYRAZINE;2-Bromopyrazino[4,5-a]pyrole
• CAS NO: 912773-24-1
• Molecular Formula: C₆H₄BrN₃
• Molecular Weight: 198.02
• Product Categories: Fused Ring Systems;Halides;Heterocycles series
• Mol File: 912773-24-1.mol

Chemical Properties

• Appearance: /
• Density: 1.89
• Refractive Index: 1.751
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 2.60±0.30(Predicted)
• CAS DataBase Reference: 6-Bromoimidazo[1,2-a]pyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromoimidazo[1,2-a]pyrazine(912773-24-1)
• EPA Substance Registry System: 6-Bromoimidazo[1,2-a]pyrazine(912773-24-1)

Safety Data

• Hazardous Substances Data: 912773-24-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
6-Bromoimidazo[1,2-a]pyrazine is used as a building block in organic synthesis for the creation of various biologically active molecules. Its unique structure allows for the development of new compounds with potential applications in various industries.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 6-Bromoimidazo[1,2-a]pyrazine is utilized as a key intermediate in the synthesis of pharmaceuticals. Its reactivity and structural properties enable the development of new drugs with improved therapeutic effects.
Used in Agrochemicals:
6-Bromoimidazo[1,2-a]pyrazine is also employed in the agrochemical sector as a building block for the synthesis of bioactive molecules. These molecules can be used in the development of new pesticides, herbicides, and other agrochemical products.
Used in Electronics Materials:
6-Bromoimidazo[1,2-a]pyrazine is used as an intermediate in the production of materials for electronics. Its unique properties contribute to the development of advanced electronic components and devices.
Used in Polymers:
6-Bromoimidazo[1,2-a]pyrazine is utilized in the synthesis of specialty polymers, which have specific applications in various industries due to their unique properties.
Used in Specialty Chemicals:
6-Bromoimidazo[1,2-a]pyrazine is also used in the production of other specialty chemicals, where its unique structure and reactivity contribute to the development of innovative products with specific applications.

InChI:InChI=1/C6H4BrN3/c7-5-4-10-2-1-8-6(10)3-9-5/h1-4H

Upstream product

• 59489-71-3 5-amino-2-bromopyrazine 
• 17157-48-1 bromoacetaldehyde 
• 7252-83-7 1-bromo-2,2-dimethoxyethane 
• 107-20-0 2-chloroethanal 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 

Downstream Products

• 1239441-36-1 3-chloro-6-bromoimidazo[1,2-a]pyrazine 
• 1245644-42-1 6-bromo-3-iodo-imidazo[1,2-a]pyrazine 
• 1426845-50-2 6-bromo-3-(4-fluorophenyl)imidazo[1,2-a]pyrazine 
• 1426845-10-4 2-(4-fluorophenyl)-5-(3-(4-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide 
• 1464153-41-0 (4-(imidazo[1,2-a]pyrazin-6-yl)phenyl)(4-methylpiperazin-1-yl)methanone 
• 1464153-40-9 4-(3-bromoimidazo[1,2-a]pyrazin-6-yl)benzoic acid 
• 1464150-70-6 3-fluoro-4-(6-(4-(4-methylpiperazine-1-carbonyl)phenyl)imidazo[1,2-a]pyrazin-3-yl)benzonitrile 
• 1464153-42-1 (4-(3-bromoimidazo[1,2-a]pyrazin-6-yl)phenyl)(4-methylpiperazin-1-yl)methanone 
• 1464150-76-2 (4-(3-(4-chlorophenyl)imidazo[1,2-a]pyrazin-6-yl)phenyl)(4-methylpiperazin-1-yl)methanone 
• 1464153-43-2 ethyl 4-(3-iodoimidazo[1,2-a]pyrazin-6-yl)benzoate 
• 1464150-87-5 (4-(3-(4-(2H-tetrazol-5-yl)phenyl)imidazo[1,2-a]pyrazin-6-yl)phenyl)(4-methylpiperazin-1-yl)methanone 
• 1464150-88-6 (4-methylpiperazin-1-yl)(4-(3-(4-(trifluoromethyl)phenyl)imidazo[1,2-a]pyrazin-6-yl)phenyl)methanone 
• 1464154-32-2 ethyl 4-(6-(4-(4-methylpiperazine-1-carbonyl)phenyl)imidazo[1,2-a]pyrazin-3-yl)benzoate 
• 1464153-44-3 4-(3-iodoimidazo[1,2-a]pyrazin-6-yl)benzoic acid 

Relevant articles and documents

Imidazopyrazine derivative and synthesis method and application thereof

The invention discloses 6-(6 substituent group-5-sulfonamido-3-pyridine) imidazo [1, 2-a] pyrazine derivatives as shown in a formula (I) or pharmaceutically acceptable salts thereof. The invention also discloses application of the 6-(6-substituent-5-sulfo

A novel pyrazolopyridine with in vivo activity in Plasmodium berghei- and Plasmodium falciparum-infected mouse models from structure-activity relationship studies around the core of recently identified antimalarial imidazopyridazines

Toward improving pharmacokinetics, in vivo efficacy, and selectivity over hERG, structure-activity relationship studies around the central core of antimalarial imidazopyridazines were conducted. This study led to the identification of potent pyrazolopyridines, which showed good in vivo efficacy and pharmacokinetics profiles. The lead compounds also proved to be very potent in the parasite liver and gametocyte stages, which makes them of high interest.

Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5

The present invention relates to compounds assumed to be capable of modulating the activity of the proteins ScyI1 and Grk5, thereby regulating the expression and/or release of insulin as well as to pharmaceutical compositions containing such compounds and the use thereof especially for the treatment of a metabolic disease such as diabetes, obesity and impaired adipogenesis.

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease, such as malaria, caused by a Plasmodium parasite.

Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors

Crystal structures of several urea- and thiourea-derived compounds in complex with the nicotinamide phosphoribosyltransferase (Nampt) protein were utilized to design a potent amide-containing inhibitor bearing an aza-indole moiety (7, Nampt BC IC50 = 9.0 nM, A2780 cell proliferation IC 50 = 10 nM). The Nampt-7 cocrystal structure was subsequently obtained and enabled the design of additional amide-containing inhibitors which incorporated various other fused 6,5-heterocyclic moieties and biaryl sulfone or sulfonamide motifs. Additional modifications of these molecules afforded many potent biaryl sulfone-containing Nampt inhibitors which also exhibited favorable in vitro ADME properties (microsomal and hepatocyte stability, MDCK permeability, plasma protein binding). An optimized compound (58) was a potent inhibitor of multiple cancer cell lines (IC50 10 nM vs U251, HT1080, PC3, MiaPaCa2, and HCT116 lines), displayed acceptable mouse PK properties (F = 41%, CL = 52.4 mL/min/kg), and exhibited robust efficacy in a U251 mouse xenograft model.

SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases

A range of 3,6-di(hetero)arylimidazo[1,2-a]pyrazine ATP-competitive inhibitors of CHK1 were developed by scaffold hopping from a weakly active screening hit. Efficient synthetic routes for parallel synthesis were developed to prepare analogues with improved potency and ligand efficiency against CHK1. Kinase profiling showed that the imidazo[1,2-a]pyrazines could inhibit other kinases, including CHK2 and ABL, with equivalent or better potency depending on the pendant substitution. These 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines appear to represent a general kinase inhibitor scaffold.